Colorectal Cancer — Microbiome Signature

Overview

Colorectal cancer (CRC) is the third-most-common cancer worldwide, affecting ~1.9 million people annually. The conventional view treats CRC as an age-related genetic disease driven by APC mutations and chromosomal instability. The microbiome signature framework reveals CRC as an ecological disease driven by oral pathogen colonization, secondary bile acid metabolism, iron-dependent dysbiosis, and epithelial barrier disruption.

This signature integrates 28 peer-reviewed papers spanning cross-sectional studies (n=24,000+), metagenomic analyses, metabolomics, Mendelian randomization studies, and animal models of CRC pathogenesis. Key findings include:

  1. Consistent oral pathogen enrichment across young-onset and old-onset CRC, CMS subtypes, and geographic populations [1]
  2. Stage-specific microbial markers: adenoma biomarkers are distinct from CRC biomarkers, and both are distinct from healthy controls [2]
  3. Iron-dependent dysbiosis: fermentative anaerobes exploit iron-rich tumor microenvironment; SCFA producers are competitively excluded [3]
  4. Interkingdom ecological reshaping: Candida biofilms and bacteria co-evolve in hypoxic, acidic CRC microenvironment [4]
  5. Bile acid-driven cancer stem cell generation: secondary bile acids (DCA, LCA) directly induce stemness and drug resistance via M3R/Wnt pathways [5]

Metallomic Signature

CRC is characterized by a distinctive metallomic signature that selects for pathogenic taxa and creates conditions for epithelial transformation. Unlike endometriosis (with uniform multi-metal elevation), CRC shows localized iron and zinc enrichment in the tumor microenvironment, with systemic patterns varying by stage and sidedness.

Elevated Metals

Iron (Fe) is the dominant selective pressure in CRC [6]:

  • Tumor microenvironments are characteristically iron-rich due to hemorrhage, epithelial barrier disruption, and hepcidin elevation (nutritional immunity response)
  • Siderophore-producing pathogens (E. coli, B. fragilis) exploit this iron-rich niche for biofilm formation and virulence factor synthesis
  • Iron limitation in healthy individuals (via hepcidin-mediated sequestration) is overridden by local hemorrhage and barrier disruption in tumors

Zinc (Zn) is elevated in tumor-associated dysbiosis:

  • Metalloprotease-producing pathogens require zinc cofactors
  • Calprotectin elevation in CRC (immune response to dysbiosis) sequesters zinc systemically
  • Local zinc availability in epithelial damage zones drives selection for Zn-dependent pathogens

Cadmium (Cd) and Lead (Pb) contribute to environmental burden:

  • Both accumulate in colonic tissue from dietary sources, water, and occupational exposure
  • Mis-metallation effects (Ca channel entry) displace Zn and Fe from critical enzymes
  • Synergistic oxidative stress when combined with dysbiosis-driven inflammation

Butyrate depletion is the most critical "metallomic" feature in CRC (though technically a bacterial metabolite, not a metal):

  • Short-chain fatty acid-producing bacteria (Lachnospiraceae, Ruminococcus, Faecalibacterium) are functionally depleted in the CRC microenvironment
  • This is NOT due to low dietary fiber alone — it is competitive exclusion by pathogenic taxa exploiting iron-rich, hypoxic, acidic conditions [7]
  • Butyrate depletion removes the primary anti-inflammatory and tumor-suppressive metabolite

Environmental Exposures

Sources of the metallomic and dysbiotic burden in CRC include:

ExposureMechanismEvidence
Antibiotic useBroad-spectrum antibiotics disrupt protective SCFA producers; 8-year lag to CRC diagnosis suggests chronic microbiome damageES = 1.70 (95% CI 1.26-2.30) for broad-spectrum; non-linear dose-response [8]
Red meat consumptionHeme iron and heterocyclic amines select for siderophore-producing pathogens; N-nitroso compounds drive mutagenesisDocumented in [9]
Low dietary fiberFiber fermentation produces SCFAs; fiber depletion removes the protective metabolite and selects for proteolytic pathogens[7]
Alcohol consumptionAcetaldehyde metabolism via dysbiotic microbiota; alterations in Bacteroidetes/Firmicutes ratio; oxidative stress[9]
SmokingIntroduces metals (Cd, Pb, Ni) and disrupts oxygen gradients; smoking history linked to Bacilli/Streptococcaceae enrichment[10]
Metabolic disease (obesity, diabetes, hypertension)Dysbiotic microbiota associated with metabolic inflammation; hyperglycemia and dyslipidemia feed pathogenic taxa[10]
High cholesterol dietLDL-enriched environment drives CRC progression; Lactobacillus supplementation mitigates via bile acid remodeling[11]

Nutritional Immunity Response

The host immune system is actively fighting the dysbiotic burden, with inflammatory markers elevated across all CRC stages [12]:

FactorRolePattern
IL-6, TNF-alpha, IL-1betaPro-inflammatory cytokines driving NF-kB activation and epithelial barrier disruptionChronically elevated (74.1% of papers document inflammation in CRC)
Lipopolysaccharide (LPS)Gram-negative endotoxin from oral pathogens; TLR4 activation drives carcinogenic signalingDocumented in 59.3% of papers; direct F. nucleatum LPS contribution [12]
HepcidinIron sequestration response; indicates functional iron-deficiency stateElevated in CRC, attempting to starve iron-dependent pathogens
Calprotectin, Lipocalin-2Metal chelation (zinc, iron) and siderophore antagonism; host defense against metal-dependent pathogensElevated as nutritional immunity response
IL-10 (paradoxical)Anti-inflammatory cytokine, but causally linked to increased CRC risk (OR = 1.49) via MR analysis [13]Suggests IL-10 may be exploited by pathogens for immune evasion
IgA, Regulatory T cellsReduced mucosal IgA and Treg cell populations indicate failed oral tolerance to dysbiotic taxaDepleted in CRC vs. healthy

The host is "winning" in terms of metal sequestration but "losing" in terms of barrier integrity and epithelial function — indicating that nutritional immunity alone is insufficient without restoration of protective bacteria.

Mis-metallation Events

Iron-driven epithelial barrier dysfunction is the primary mis-metallation event in CRC:

  1. Heme iron from red meat and hemorrhage accumulates in the colon
  2. Fenton chemistry catalyzes oxidative damage to epithelial tight junctions (claudins, occludin, zonula occludens-1)
  3. Barrier disruption allows translocation of bacterial LPS and pathogenic taxa
  4. Siderophore-producing pathogens exploit the iron-rich, damaged microenvironment to form biofilms and establish persistent infection

Additionally, dysbiosis-driven hypoxia alters local metal bioavailability:

  • Anaerobic pathogens preferentially express metal-dependent enzymes (FadA, BFT toxin, colibactin)
  • Hypoxia-driven epithelial hypoxia-inducible factor (HIF) activation further destabilizes barrier function and selects for anaerobes

Taxonomic Analysis

Enriched Taxa

TaxonMetal DependenciesKey Virulence EnzymesPathogenic Mechanisms
fusobacterium nucleatumFe, NiFadA (E-cadherin disruption), Fap2 (NK evasion), LPS-TLR4Canonical CRC driver — present in 70.5-82.1% of tumors across cohorts; FadA activates beta-catenin-mediated proliferation; Fap2 binds TIGIT on NK cells preventing cytotoxicity; direct immune evasion [1]
fusobacterium variumFe, NiLPS, adhesinsEarlier enrichment than F. nucleatum — present in ~80% of adenomas; FV appears before FN in adenoma-carcinoma sequence, suggesting FV may be the initiating pathogen [14]
bacteroides fragilisZn, FeBFT toxin (Zn-dependent), hydrogenase (Fe), beta-glucuronidaseEnterotoxigenic ETBF strains; BFT induces IL-17 and colorectal inflammation; biofilm formation [1]
parvimonas micraFe, NiSiderophores, adhesinsOral pathogen universally enriched in CRC; top biomarker across populations; independent biomarker strength despite methodological differences (16S vs shotgun) [15]
peptostreptococcus stomatisFeColibactin (pks operon)Oral pathogen; pks+ strains induce DNA double-strand breaks; enriched in advanced CRC stages [1]
escherichia coliFe, Zn, NiSiderophores, pks colibactin, urease, glyoxalasepks+ E. coli strains produce colibactin toxin inducing 8x higher mutation rates; siderophore competition; exploits iron-rich CRC microenvironment [12]
clostridium symbiosumFeBile acid metabolism enzymesCRC driver taxon — enriched in both yCRC and oCRC; bile acid-metabolizing Clostridium species convert primary to secondary bile acids (DCA/LCA) [1]
akkermansia muciniphilaMucin-degrading enzymesParadoxical enrichment: 4-fold elevated in CRC stool vs healthy [16]; produces succinate and propionate from mucin metabolism; maintains glycerophospholipid pathways critical for PD-1 checkpoint escape [6]; NOT protective in CRC context
candida albicansNi (biofilm)Biofilm formation, functional shieldingInterkingdom driver: elevated in CRC (qPCR-validated); forms mixed biofilms with bacteria; consumes oxygen creating anaerobic pockets; shields bacteria from immune detection; cross-kingdom dysbiosis indicator [4]
porphyromonas gingivalisFeLPS, fimbriaeOral pathogen specific to CMS1 (immune-inflamed) subtype; periodontal disease is a risk factor for CRC; gut-oral axis connection [17]

Depleted Taxa

TaxonNormal FunctionWhy LostConsequence
lachnospiraceaeButyrate production (primary SCFA generator)Iron-rich, hypoxic CRC microenvironment; competitive exclusion by siderophore-producing pathogens; MR-causal protective effect suggests active dysbiosis-driven lossLoss of HDAC inhibition and GPR109A signaling; epithelial barrier dysfunction; loss of Treg induction
faecalibacterium prausnitziiButyrate production; anti-inflammatory polysaccharide A (PSA)Competitive exclusion in dysbiotic state; sensitivity to oxidative stress from inflammationLoss of anti-inflammatory signals; major microbial biomarker of healthy microbiota
roseburiaButyrate production; SCFA fermentationIron-rich, anaerobic tumor microenvironment despite being facultative anaerobesParadoxically found in tumor tissue but at lower abundance than in adjacent normal tissue — suggests "passenger" recruitment rather than driver status [18]
prevotella copriFiber fermentation; SCFA productionFiber depletion in Western diet; competitive exclusion by proteolytic pathogens in dysbiotic state40-fold depletion in CRC; marker of protective healthy microbiota
ruminococcus albusCellulose and fiber fermentation; SCFA productionHypoxia, low fiber substrate availability, iron-rich toxin-producing environment10-fold depletion; loss of plant polysaccharide processing
dialister invisusShort-chain fatty acid productionIron-rich, dysbiotic CRC microenvironment48.7-fold depletion; loss of protective SCFA producer

Virulence Enzymes and Features

The enriched taxa in CRC express a consistent, overlapping set of metal-dependent virulence enzymes [12]:

Enzyme/FactorMetal CofactorFunctionPathogensCarcinogenic Role
FadA adhesinDisrupts E-cadherin junctions; activates beta-catenin signalingF. nucleatumDrives epithelial proliferation; breaks epithelial-mesenchymal barriers; enables translocation
Fap2 lectinBinds TIGIT checkpoint receptor on NK cells; immune evasionF. nucleatumPrevents NK cell-mediated killing; enables persistence and biofilm formation
BFT toxinZnZonula occludens-1 (ZO-1) cleavage; epithelial barrier disruptionB. fragilis ETBFLeaky gut → increased LPS translocation → TLR4 activation → NF-kB-driven inflammation
Colibactin (pks operon)Double-strand DNA break induction; 8x mutation rate elevationpks+ E. coli, P. stomatisDirect mutagenesis; drives adenoma-carcinoma progression
LPS (gram-negative endotoxin)TLR4 activation; NF-kB inflammasome activationF. nucleatum, E. coli, B. fragilis, etc.Chronic innate immune activation; epithelial barrier dysfunction; autophagic response promoting drug resistance [12]
SiderophoresFe acquisitionIron chelation and uptake in iron-rich tumor microenvironmentE. coli, B. fragilisBiofilm formation; virulence factor synthesis; competitive nutrient exclusion
UreaseNipH elevation in tumor microenvironmentVarious EnterobacteriaceaeMay reduce local acidity needed for SCFA penetration
Beta-glucuronidaseEstrogen deconjugation (estrobolome pathway, though less studied in CRC than endometriosis)E. coli, B. fragilis, F. nucleatumPossible hormone-driven epithelial proliferation (secondary effect)
Nitrite reductaseFe, MoNitrite metabolism; anaerobic respirationVarious anaerobesEnables colonization in hypoxic tumor niche

Interkingdom Relationships

Bacteria-fungal co-evolution is a defining feature of CRC dysbiosis [4]:

Candida albicans role:

  • Significantly enriched in CRC (qPCR-validated increase across Chinese cohort)
  • Forms tight biofilms with bacterial pathogens (F. nucleatum, E. coli, Bacteroides)
  • Fungal-bacterial co-aggregates show reduced inflammatory detection compared to bacteria alone
  • Candida biofilms consume oxygen → anaerobic pockets for strict/facultative anaerobes (F. nucleatum, B. fragilis)
  • Cross-kingdom dysbiosis (negative bacterial-fungal correlation, R = -0.17 to -0.32) indicates antagonistic interactions suggesting fungal "takeover" in dysbiotic state

Oral pathogen-gut dysbiosis link:

  • Periodontal pathogens (P. gingivalis, F. nucleatum, T. denticola, T. forsythia) are found in colonic tissues, not just stool
  • This is a true translocation event, not oral contamination of stool samples [17]
  • Suggested mechanisms: (1) periodontal inflammation increases systemic inflammation enabling gut translocation; (2) bacteremia from dental procedures; (3) swallowing of periodontal bacteria during mastication followed by colonic colonization

Ecological State

The CRC tumor microenvironment is characterized by specific ecological conditions that select for pathogenic taxa and exclude protective SCFA producers:

Hypoxia and Anaerobic Metabolism

The tumor microenvironment is constitutively hypoxic due to:

  • Tumor size exceeding diffusion distance (>200 micrometers)
  • Microvascular dysfunction and hemorrhage
  • Oxygen consumption by inflammatory cells and anaerobic pathogenic bacteria
  • Reduced mucus oxygenation from dysbiosis-driven barrier disruption

This selects for strict and facultative anaerobes (F. nucleatum, B. fragilis, Peptostreptococcus, Candida) while excluding oxygen-preferring commensals.

Bile Acid-Driven Selection

The CRC microenvironment shows secondary bile acid accumulation [19]:

  • Primary bile acids (cholate, chenodeoxycholate) are deconjugated and 7-alpha-dehydroxylated by dysbiotic bacteria
  • Deoxycholic acid (DCA) and lithocholic acid (LCA) accumulate in CRC tissue
  • DCA/LCA directly induce cancer stem cell markers (CD44, CD166, ALDH1A1) via M3R-mediated Wnt/beta-catenin signaling [5]
  • DCA/LCA activate EGFR and increase MMP expression, promoting epithelial-mesenchymal transition and drug resistance

This creates a positive feedback loop: dysbiosis → secondary bile acid accumulation → cancer stem cell induction → further epithelial barrier disruption → further dysbiosis.

Iron-Rich, Acidic Microenvironment

The CRC microenvironment combines:

  • High iron concentration from hemorrhage and epithelial barrier breakdown
  • Low pH from fermentative anaerobes producing lactate and short-chain fatty acids
  • Low oxygen saturation from biofilm formation and aerobic respiration by inflammatory cells

This creates selective pressure favoring:

  • Siderophore-producing pathogens (E. coli, B. fragilis)
  • Acid-tolerant pathogens (F. nucleatum, peptostreptococci)
  • Biofilm-forming communities (Candida + bacteria)

SCFA Depletion and Loss of Barrier Function

The CRC microenvironment is depleted in short-chain fatty acids because:

  1. SCFA-producing bacteria (Lachnospiraceae, Ruminococcus) are competitively excluded
  2. Remaining SCFA production is insufficient to activate GPR109A and FFAR2 on epithelial cells and immune cells
  3. Loss of HDAC inhibition by butyrate → loss of epigenetic tumor suppression
  4. Loss of GPR109A signaling → loss of Treg induction and IL-22 production for barrier integrity

This is not primarily due to fiber depletion — even high-fiber diets may fail in the presence of dominant pathogenic taxa that ferment other substrates preferentially.

Metabolic Disruption: Tryptophan and Serotonin Depletion

A striking finding from metabolomics is the complete absence of serotonin and tryptophan metabolites (including 5-HIAA) in CRC tumor tissue compared to adjacent normal tissue [3]:

  • Healthy colon tissue produces serotonin from tryptophan via enteroendocrine cells and commensal bacteria
  • CRC tumor tissue shows zero detection of serotonin, 5-HIAA, and tryptophan metabolites
  • This disruption correlates with dysbiotic microbiota unable to produce tryptophanase-positive bacteria

The loss of serotonergic signaling in tumors may:

  • Reduce 5-HT4 receptor signaling necessary for epithelial barrier integrity
  • Enhance tumor cell proliferation (tumors express 5-HT2B receptors)
  • Suppress immune cell function (T cells require serotonin for IL-2 production)

Pathogenic Ecosystem Assembly: Driver vs. Passenger Model

A critical distinction has emerged from multi-cohort analyses [20], [21]:

Driver bacteria initiate dysbiosis and epithelial transformation:

  • Fusobacterium varium (adenoma stage)
  • Fusobacterium nucleatum (carcinoma stage)
  • pks+ E. coli (colibactin-driven mutagenesis)

Passenger bacteria are recruited by the altered tumor microenvironment but are not primary drivers:

  • Roseburia and Faecalibacterium (SCFA producers) are enriched in tumor tissue but depleted in stool, suggesting selective recruitment to the tumor by iron/lactate availability
  • Akkermansia muciniphila is 4-fold elevated in CRC stool but acts as an immune-evasion helper, not a primary driver

This model explains why eliminating passenger bacteria (with antibiotics or probiotics) alone is insufficient — the driver taxa must be addressed, and the ecological conditions that favor their persistence must be reversed.

Validated Interventions

Note: CRC interventions are clinically less well-studied than endometriosis. The following are supported by mechanistic evidence and/or animal models, but clinical RCT validation is limited.

Dietary Interventions

InterventionMechanismEvidence Level
High dietary fiberRestores SCFA-producing bacteria; butyrate supports barrier integrity and Treg inductionEpidemiological; mechanistic via GPR109A/FFAR2
Reduced red meatLowers heme iron and heterocyclic amines; reduces siderophore-dependent pathogen selectionEpidemiological
Fermented foods / BifidobacteriumPolyphenols act as prebiotics; Bifidobacterium produces short-chain fatty acidsMechanistic
Ketogenic dietIncreases beta-hydroxybutyrate and primary bile acids; restores Muribaculaceae and Akkermansia; FXR upregulation and NF-kB suppressionAOM/DSS animal model [19]; promising but not clinically validated

Microbial Competition / Probiotic Interventions

InterventionMechanismEvidence Level
Fecal Microbiota Transplantation (FMT)Restores protective SCFA producers; reverses dysbiosisAnimal model; one trial ongoing (NCT04729322)
Lactobacillus plantarum supplementationRestores SCFA-producing bacteria; reduces inflammatory markers and tumor growthAnimal model [11]; mechanistic
Prebiotics (inulin, PHGG)Selectively feed protective bacteria; restore butyrate productionMechanistic; limited clinical data

Checkpoint Inhibitor + Microbiome Modulation

InterventionMechanismEvidence Level
Anti-PD-1/PD-L1 + protective microbiotaSpecific taxa (Akkermansia, Prevotella, Bifidobacterium) maintain PD-1 antibody efficacy; dysbiotic microbiota reduces responseAnimal model; clinical trial underway [22]
Vancomycin pretreatment for selectivityVancomycin selectively eliminates gram-positive organisms; preserved gram-negative Bacteroides and Prevotella enhance PD-1 responseCT26 tumor model [6]

STOPs

  • STOP: Iron Supplementation for Colorectal Cancer — CRC tumors actively sequester iron, and the characteristic pathobionts (Fusobacterium nucleatum, pks+ E. coli) are siderophore-dependent iron foragers whose virulence is directly iron-dependent; supplementation feeds the same microbial ecology that drove oncogenesis. Evidence: cross-sectional.

CRC-specific STOPs (counterproductive interventions) are less well-documented than endometriosis STOPs, but emerging data suggest:

  • Broad-spectrum antibiotics in high-risk populations: While antibiotics may reduce immediate dysbiotic burden, broad-spectrum agents eliminate protective SCFA producers; long-term antibiotic use is associated with increased CRC risk (OR 1.17, 95% CI 1.05-1.30) with 8-year latency [8]
  • Probiotic intervention without prebiotic support: Supplementing probiotics without simultaneous fiber/prebiotic intake may fail because the dysbiotic microenvironment selects against SCFA-producing strains even when exogenously provided

Open Questions

  • FMT efficacy in humans: Animal models show dramatic CRC suppression with FMT; when will clinical trials report outcomes?
  • Periodontal-CRC causality: Is the oral-gut-CRC link one-way (translocation) or bidirectional (systemic inflammation priming the colon)?
  • Driver bacteria identification for young-onset CRC: Fusobacterium varium appears dominant in adenomas; what drives F. nucleatum enrichment in established carcinoma?
  • Serotonergic disruption mechanism: Does dysbiotic microbiota actively suppress tryptophanase-positive bacteria, or is this a passive loss due to oxygen depletion?
  • Candida's role in adenoma progression: Is Candida present in adenomas? Does interkingdom dysbiosis accelerate the adenoma-carcinoma sequence?
  • CMS subtype-specific interventions: CMS1 is oral pathogen-enriched; are different taxa dominant in CMS2, CMS3, CMS4? Should interventions be subtype-specific?
  • Iron chelation therapy: Could chelation agents (e.g., phytic acid, lactoferrin) combined with anti-pathogenic interventions accelerate SCFA producer restoration?

Knowledge Primitives Applied

CRC pathogenesis engages multiple Karen's Brain primitives:

  1. Metals as Selective Pressures — Iron-rich tumor microenvironment selects for siderophore-producing pathogens; heme iron from red meat increases CRC risk via dysbiosis-driven selection
  2. Nutritional Immunity as Interpretive Constraint — Hepcidin elevation and calprotectin-mediated zinc sequestration are host defense mechanisms, not deficiency
  3. Mis-metallation and Toxic Metal Entry — Iron-driven Fenton chemistry damages epithelial tight junctions; cadmium/lead accumulation from diet and water contribute to oxidative stress
  4. Microbial Metal Dependencies as Achilles' Heels — Iron restriction via hepcidin is protective; siderophore inhibitors may disable pathogenic biofilms
  5. Two-Sided Ecological Engineering — Suppress pathogenic taxa (antibiotics, probiotics) AND restore SCFA producers (fiber, prebiotics, FMT); one-sided interventions fail
  6. Interkingdom Relationships and Functional Shielding — Candida-bacterial biofilms shield pathogens from immune detection; cross-kingdom dysbiosis is a CRC hallmark
  7. Estrobolome and Hormone Recirculation — Secondary bile acids drive cancer stem cell generation (DCA/LCA via M3R/Wnt pathways); less prominent than endometriosis but present
  8. Siderophore Competition and Iron Ecology — Iron-dependent biofilm formation by E. coli and B. fragilis; FMT likely works via superior siderophore systems of commensal taxa
  9. Oxygen State as Ecological Determinant — Hypoxia selects for anaerobes; oxygenation via barrier restoration (fiber, SCFA) as therapeutic pathway

—-

Note: This signature is marked as `cureva_status: partial` because robust clinical intervention data (validated interventions with human RCT evidence and mechanistic triangle closure) is limited for CRC. The signature integrates strong mechanistic evidence but awaits larger clinical trials to validate interventions similar to endometriosis. Key gaps: no human clinical P-M-D triangles for dietary interventions; no FMT human trial results yet published; no HBOT or chelation therapy data specific to CRC.

Key Sources

References (25)

  1. Youwen Qin, Xin Tong, Wei-Jian Mei et al. (2024). Consistent signatures in the human gut microbiome of old- and young-onset colorectal cancer. Nature Communications. doi:10.1038/s41467-024-47523-x
  2. Wu Y, Jiao N, Zhu R et al. (2021). Identification of Microbial Markers across Populations in Early Detection of Colorectal Cancer. Nature Communications. doi:10.1038/s41467-021-23265-y
  3. Loke MF, Chua EG, Gan HM et al. (2018). Metabolomics and 16S rRNA Sequencing of Human Colorectal Cancers and Adjacent Mucosa. PLOS ONE. doi:10.1371/journal.pone.0208584
  4. Xiaopeng Li, Jiahui Feng, Zhanggui Wang et al. (2023). Features of combined gut bacteria and fungi from a Chinese cohort of colorectal cancer, colorectal adenoma, and post-operative patients. Frontiers in Microbiology. doi:10.3389/fmicb.2023.1236583
  5. Lulu Farhana, Pratima Nangia-Makker, Evan Arbit et al. (2016). Bile acid: a potential inducer of colon cancer stem cells. Stem Cell Research & Therapy. doi:10.1186/s13287-016-0439-4
  6. Xinjian Xu, Ji Lv, Fang Guo et al. (2020). Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. Frontiers in Microbiology. doi:10.3389/fmicb.2020.00814
  7. Maria Daniella Carretta, John Quiroga, Rodrigo Lopez et al. (2021). Participation of short-chain fatty acids and their receptors in gut inflammation and colon cancer. Frontiers in Physiology. doi:10.3389/fphys.2021.662739
  8. Johanna Simin, Romina Fornes, Qing Liu et al. (2020). Antibiotic Use and Risk of Colorectal Cancer: A Systematic Review and Dose-Response Meta-Analysis. British Journal of Cancer
  9. Appunni S, Rubens M, Ramamoorthy V et al. (2021). Emerging Evidence on the Effects of Dietary Factors on the Gut Microbiome in Colorectal Cancer. Frontiers in Nutrition. doi:10.3389/fnut.2021.718389
  10. Tung Hoang, Minjung Kim, Ji Won Park et al. (2023). Dysbiotic microbiome variation in colorectal cancer patients is linked to lifestyles and metabolic diseases. BMC Microbiology. doi:10.1186/s12866-023-02771-7
  11. Xiaoliang Xie, Wenjing Wang, Haiming Zhang et al. (2025). Cholesterol-induced colorectal cancer progression and its mitigation through gut microbiota remodeling and simvastatin treatment. BMC Cancer. doi:10.1186/s12885-025-14379-3
  12. Hanus M, Parada-Venegas D, Landskron G et al. (2021). Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment. Frontiers in Immunology. doi:10.3389/fimmu.2021.612826
  13. Ma M, Zheng Z, Li J et al. (2024). Association between the Gut Microbiota, Inflammatory Factors, and Colorectal Cancer: Evidence from Mendelian Randomization Analysis. Frontiers in Microbiology. doi:10.3389/fmicb.2024.1309111
  14. Saito K, Koido S, Odamaki T et al. (2019). Metagenomic Analyses of the Gut Microbiota Associated with Colorectal Adenoma. PLOS ONE. doi:10.1371/journal.pone.0212406
  15. Bars-Cortina D, Ramon E, Rius-Sansalvador B et al. (2024). Comparison between 16S rRNA and Shotgun Sequencing in Colorectal Cancer, Advanced Colorectal Lesions, and Healthy Human Gut Microbiota. BMC Genomics. doi:10.1186/s12864-024-10621-7
  16. Tiffany L Weir, Daniel K Manter, Amy M Sheflin et al. (2013). Stool Microbiome and Metabolome Differences between Colorectal Cancer Patients and Healthy Adults. PLoS ONE. doi:10.1371/journal.pone.0070803
  17. Rachel V. Purcell, Martina Visnovska, Patrick J. Biggs et al. (2017). Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Scientific Reports. doi:10.1038/s41598-017-11237-6
  18. Marchesi JR, Dutilh BE, Hall N et al. (2011). Towards the Human Colorectal Cancer Microbiome. PLOS ONE. doi:10.1371/journal.pone.0020447
  19. Qinhan Gao, Yuwen Liu, Fayu Su et al. (2026). Ketogenic diet suppresses colorectal cancer through reshaping gut microbiota and modulating the intestinal FXR/NF-kB signaling pathway. Food Science and Human Wellness. doi:10.26599/FSHW.2025.9250565
  20. Zhiguang Gao, Bomin Guo, Renyuan Gao et al. (2015). Microbiota disbiosis is associated with colorectal cancer. Frontiers in Microbiology. doi:10.3389/fmicb.2015.00020
  21. Lan Zhao, William C. Cho, Mark R. Nicolls (2021). Colorectal cancer-associated microbiome patterns and signatures. Frontiers in Genetics. doi:10.3389/fgene.2021.787176
  22. Hou X, Zheng Z, Wei J et al. (2022). Effects of Gut Microbiota on Immune Responses and Immunotherapy in Colorectal Cancer. Frontiers in Immunology. doi:10.3389/fimmu.2022.1030745
  23. Shaomin Zou, Chao Yang, Jieping Zhang et al. (2024). Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer. Journal of Translational Medicine. doi:10.1186/s12967-024-04984-4
  24. Yu L, Zhao G, Wang L et al. (2022). A Systematic Review of Microbial Markers for Risk Prediction of Colorectal Neoplasia. British Journal of Cancer. doi:10.1038/s41416-022-01740-7
  25. Liu Z, Zhou X, Kuang L et al. (2025). Novel Insights into Immune-Gut Microbiota Interactions in Colorectal Cancer: A Mendelian Randomization Study. Infectious Agents and Cancer. doi:10.1186/s13027-025-00653-3